• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:刘宇海,张嘉辰,刘金毅,肖妍.慢性乙型肝炎临床治愈新药组合与个性化治疗研究进展[J].药学研究,2026,45(5):577-586[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 1688次   下载 761次 本文二维码信息
码上扫一扫!
慢性乙型肝炎临床治愈新药组合与个性化治疗研究进展
刘宇海1,张嘉辰1,刘金毅1,肖妍2
字体:加大+|默认|缩小-
(1.北京三元基因药业股份有限公司,北京 102600;2.中国食品药品检定研究院,北京 100050)
摘要:
本综述聚焦慢性乙型肝炎临床治愈领域,着重探讨新型药物组合在个性化治疗中展现的巨大潜力。随着对慢性乙型肝炎发病机制理解的深入,新型药物研发取得显著进展。不同作用机制的药物巧妙组合,如靶向病毒复制关键环节的药物与调节宿主免疫反应的药物联用,为实现临床治愈开辟了新路径。考虑到患者在基因多态性、免疫状态及疾病进展阶段等方面的个体差异,依据患者特征精准匹配药物组合的个性化治疗策略,已成为当下研究热点。文章全面梳理相关研究成果,详细分析新型药物组合的疗效、安全性,以及个性化治疗中药物选择与应用的实施路径和面临的挑战,旨在为慢性乙型肝炎临床治愈的进一步探索提供坚实的药物应用理论依据与实践参考,助力优化基于药物的治疗方案,切实提升患者临床治愈的可能性。
关键词:  慢性乙型肝炎  临床治愈  新型药物组合  个性化治疗
DOI:10.13506/j.cnki.jpr.2026.05.014
基金项目:
收稿日期:2025-05-27   修回日期:2025-07-09   出版日期:2026-05-29
Research progress on new drug combinations and personalized treatment for clinical cure of chronic hepatitis B
LIU Yuhai1,ZHANG Jiachen1,LIU Jinyi1,XIAO Yan2
(1.Beijing Tri-Prime Gene Pharmaceutical Co., Ltd.,Beijing 102600,China;2.National Institutes for Food and Drug Control,Beijing 100050,China)
Abstract:
This review focused on the field of clinical cure of chronic hepatitis B, with an emphasis on exploring the great potential of novel drug combinations in personalized treatment. With the deepening of the understanding of the pathogenesis of chronic hepatitis B, significant progress has been made in the research and development of new drugs. The ingenious combination of drugs with different mechanisms of action, such as the combination of drugs targeting key links of viral replication and drugs regulating the host immune response, has opened up a new path for achieving clinical cure. Considering the individual differences among patients in terms of genetic polymorphism, immune status, and disease progression stage, the personalized treatment strategy of precisely matching drug combinations based on patient characteristics has become a current research hotspot. This article comprehensively combs through relevant research achievements, and conducts a detailed analysis of the efficacy and safety of novel drug combinations, as well as the implementation paths and challenges faced in the selection and application of drugs in personalized treatment. It aims to provide a solid theoretical basis and practical reference for drug application for the further exploration of clinical cure of chronic hepatitis B, facilitate the optimization of drug-based treatment regimens, and effectively improve the possibility of clinical cure for patients.
Key words:  Chronic hepatitis B  Clinical cure  Novel drug combinations  Personalized treatment
今日访问量:2274    总访问量:55338616
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司